FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2339998564> ?p ?o ?g. }

• W2339998564 endingPage "442" @default.
• W2339998564 startingPage "436" @default.
• W2339998564 abstract "Background Ischemia-reperfusion injury (I/R) is an inflammatory response to hypoxia that is dependent on antibodies. We have previously shown that the N2 peptide blocks binding of autoreactive antibody to ischemic tissue and reduces I/R injury in rodents. Whether these same antibodies exist and target the same antigen in humans is unknown. In this study, we create a novel “humanized” mice model of intestinal I/R and test the efficacy of N2. Methods Humanized mice were generated by transplanting human lymphocytes into immunodeficient mice. Human T- and B-cell engraftment in the spleen and peritoneum was confirmed using flow cytometry, and circulating human antibody in mouse serum was measured with ELISA. Injury in the small intestine and lung after intestinal I/R was measured in the presence or absence of N2. Immunohistochemistry was used to assess for human antibody deposition in the small intestine. Results Humanized mice engrafted with functional CD20+ B cells generated high circulating serum levels of human antibody. N2 treatment significantly reduced intestinal injury severity scores after I/R (control: 28 ± 1.5, N2: 9.1 ± 3.4; P < .05). N2 also attenuated remote lung inflammation after I/R (control: 28 ± 4, N2: 5.4 ± 1.3; P < .05). Protection from I/R injury correlated with blockade of human antibody deposition on small intestine. Conclusion N2 is an effective therapy for I/R injury in the presence of human immunity, supporting a conserved target of inflammatory attack in human reperfusion injury. Ischemia-reperfusion injury (I/R) is an inflammatory response to hypoxia that is dependent on antibodies. We have previously shown that the N2 peptide blocks binding of autoreactive antibody to ischemic tissue and reduces I/R injury in rodents. Whether these same antibodies exist and target the same antigen in humans is unknown. In this study, we create a novel “humanized” mice model of intestinal I/R and test the efficacy of N2. Humanized mice were generated by transplanting human lymphocytes into immunodeficient mice. Human T- and B-cell engraftment in the spleen and peritoneum was confirmed using flow cytometry, and circulating human antibody in mouse serum was measured with ELISA. Injury in the small intestine and lung after intestinal I/R was measured in the presence or absence of N2. Immunohistochemistry was used to assess for human antibody deposition in the small intestine. Humanized mice engrafted with functional CD20+ B cells generated high circulating serum levels of human antibody. N2 treatment significantly reduced intestinal injury severity scores after I/R (control: 28 ± 1.5, N2: 9.1 ± 3.4; P < .05). N2 also attenuated remote lung inflammation after I/R (control: 28 ± 4, N2: 5.4 ± 1.3; P < .05). Protection from I/R injury correlated with blockade of human antibody deposition on small intestine. N2 is an effective therapy for I/R injury in the presence of human immunity, supporting a conserved target of inflammatory attack in human reperfusion injury." @default.
• W2339998564 created "2016-06-24" @default.
• W2339998564 creator A5009924971 @default.
• W2339998564 creator A5047151049 @default.
• W2339998564 creator A5066858437 @default.
• W2339998564 creator A5081180580 @default.
• W2339998564 creator A5086010689 @default.
• W2339998564 date "2016-08-01" @default.
• W2339998564 modified "2023-10-17" @default.
• W2339998564 title "Prevention of intestinal ischemia-reperfusion injury in humanized mice" @default.
• W2339998564 cites W1547029341 @default.
• W2339998564 cites W1563439029 @default.
• W2339998564 cites W1913397935 @default.
• W2339998564 cites W1965989818 @default.
• W2339998564 cites W1970228545 @default.
• W2339998564 cites W1973173201 @default.
• W2339998564 cites W1990159135 @default.
• W2339998564 cites W2001682169 @default.
• W2339998564 cites W2004801769 @default.
• W2339998564 cites W2006165088 @default.
• W2339998564 cites W2046544896 @default.
• W2339998564 cites W2046560815 @default.
• W2339998564 cites W2050649461 @default.
• W2339998564 cites W2059699981 @default.
• W2339998564 cites W2081048670 @default.
• W2339998564 cites W2093404237 @default.
• W2339998564 cites W2103618204 @default.
• W2339998564 cites W2120522561 @default.
• W2339998564 cites W2123229364 @default.
• W2339998564 cites W2131251583 @default.
• W2339998564 cites W2145472609 @default.
• W2339998564 cites W2146388575 @default.
• W2339998564 cites W2152385872 @default.
• W2339998564 cites W2154828898 @default.
• W2339998564 cites W2157069721 @default.
• W2339998564 cites W2168147589 @default.
• W2339998564 cites W3043125680 @default.
• W2339998564 doi "https://doi.org/10.1016/j.surg.2016.03.001" @default.
• W2339998564 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4938717" @default.
• W2339998564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27086922" @default.
• W2339998564 hasPublicationYear "2016" @default.
• W2339998564 type Work @default.
• W2339998564 sameAs 2339998564 @default.
• W2339998564 citedByCount "7" @default.
• W2339998564 countsByYear W23399985642016 @default.
• W2339998564 countsByYear W23399985642017 @default.
• W2339998564 countsByYear W23399985642018 @default.
• W2339998564 countsByYear W23399985642019 @default.
• W2339998564 countsByYear W23399985642021 @default.
• W2339998564 crossrefType "journal-article" @default.
• W2339998564 hasAuthorship W2339998564A5009924971 @default.
• W2339998564 hasAuthorship W2339998564A5047151049 @default.
• W2339998564 hasAuthorship W2339998564A5066858437 @default.
• W2339998564 hasAuthorship W2339998564A5081180580 @default.
• W2339998564 hasAuthorship W2339998564A5086010689 @default.
• W2339998564 hasBestOaLocation W23399985642 @default.
• W2339998564 hasConcept C126322002 @default.
• W2339998564 hasConcept C142724271 @default.
• W2339998564 hasConcept C159654299 @default.
• W2339998564 hasConcept C203014093 @default.
• W2339998564 hasConcept C204232928 @default.
• W2339998564 hasConcept C2776156784 @default.
• W2339998564 hasConcept C2776914184 @default.
• W2339998564 hasConcept C2777882243 @default.
• W2339998564 hasConcept C2780114680 @default.
• W2339998564 hasConcept C541997718 @default.
• W2339998564 hasConcept C71924100 @default.
• W2339998564 hasConcept C8891405 @default.
• W2339998564 hasConcept C98274493 @default.
• W2339998564 hasConceptScore W2339998564C126322002 @default.
• W2339998564 hasConceptScore W2339998564C142724271 @default.
• W2339998564 hasConceptScore W2339998564C159654299 @default.
• W2339998564 hasConceptScore W2339998564C203014093 @default.
• W2339998564 hasConceptScore W2339998564C204232928 @default.
• W2339998564 hasConceptScore W2339998564C2776156784 @default.
• W2339998564 hasConceptScore W2339998564C2776914184 @default.
• W2339998564 hasConceptScore W2339998564C2777882243 @default.
• W2339998564 hasConceptScore W2339998564C2780114680 @default.
• W2339998564 hasConceptScore W2339998564C541997718 @default.
• W2339998564 hasConceptScore W2339998564C71924100 @default.
• W2339998564 hasConceptScore W2339998564C8891405 @default.
• W2339998564 hasConceptScore W2339998564C98274493 @default.
• W2339998564 hasIssue "2" @default.
• W2339998564 hasLocation W23399985641 @default.
• W2339998564 hasLocation W23399985642 @default.
• W2339998564 hasLocation W23399985643 @default.
• W2339998564 hasLocation W23399985644 @default.
• W2339998564 hasOpenAccess W2339998564 @default.
• W2339998564 hasPrimaryLocation W23399985641 @default.
• W2339998564 hasRelatedWork W1975240939 @default.
• W2339998564 hasRelatedWork W2029394706 @default.
• W2339998564 hasRelatedWork W2037001060 @default.
• W2339998564 hasRelatedWork W2292583544 @default.
• W2339998564 hasRelatedWork W2355920994 @default.
• W2339998564 hasRelatedWork W2359635637 @default.
• W2339998564 hasRelatedWork W2363406581 @default.
• W2339998564 hasRelatedWork W2394179638 @default.
• W2339998564 hasRelatedWork W2399421402 @default.

• next